Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA-Haploidentical Stem Cell Transplantation for Aggressive Sickle Cell Disease
NCT03121001Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Mar 2017
- Primary completion
- May 2029
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in sickle cell disease (SCD), sponsored by University of Illinois Chicago. Primary endpoint: Engraftment at 60 days. Started Mar 2017; status: recruiting.
02
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03121001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121001.